title: New strategies in the management of acute coronary syndromes.
abstract: Advances in the understanding of acute coronary syndromes have occurred rapidly in the last 5 years and have dramatically changed the way patients are evaluated, diagnosed, and managed. Medical advances, such as antiplatelet and antithrombin agents and growing databases on interventional outcomes have created a new world of therapeutic options for the spectrum of ischemic heart disease. As more options become available, nurses are under increasing pressure to stay abreast of what these options have to offer patients, and which patients benefit most from each therapeutic approach. The purpose of this article is to review the newest therapies for acute coronary syndromes, including GP IIb/IIIa inhibitors, low molecular weight heparins, and direct thrombin inhibitors, and discuss indications and contraindications for each of these therapies. Changes in diagnostic approach using troponin T and I are also presented.
authors.affiliation: Cardiac Intensive Care Unit, Duke University Medical Center, Durham, North Carolina, USA.
authors.forename: J
authors.initials: J
authors.lastname: Fullwood
authors.forename: G
authors.initials: G
authors.lastname: Butler
authors.forename: T
authors.initials: T
authors.lastname: Smith
authors.forename: M
authors.initials: M
authors.lastname: Cox
authors.forename: W
authors.initials: W
authors.lastname: Bride
authors.forename: Z
authors.initials: Z
authors.lastname: Mostaghimi
authors.forename: P S
authors.initials: PS
authors.lastname: Cook
authors.forename: B B
authors.initials: BB
authors.lastname: Granger
mesh_terms: D000208:Acute Disease; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy / Q000451:nursing / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans
chemical_list: D005343:Fibrinolytic Agents